Latest News and Press Releases
Want to stay updated on the latest news?
-
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also...
-
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE)...
-
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
-
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also...
-
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
-
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
-
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
-
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary...
-
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
-
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed...